POTSDAM, GERMANY--(Marketwire - November 24, 2011) -
Signature Diagnostics /
Signature Diagnostics to Present at the 23rd Annual Piper Jaffray Health Care
Conference. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Potsdam, Germany, November 24, 2011 - Signature Diagnostics AG announced today
that André Rosenthal, Chief Executive Officer of Signature Diagnostics, will
present at the 23(rd) Annual Piper Jaffray Health Care Conference on Wednesday,
November 29(th) at 11:10 a.m. Eastern Time at the New York Palace Hotel in New
York City. Dr. Rosenthal will provide an overview of the company and its
development and commercial programs including its blood-based Detector C test
suite for early detection of colorectal cancer.
About Signature Diagnostics AG
Signature Diagnostics AG is a molecular diagnostics company based in Potsdam,
Germany, focusing on the development and commercialization of novel molecular
oncology diagnostic products for early detection (screening) and prognosis of
cancer. The company has completed development of its first two diagnostic
products for colorectal cancer screening ("Detector C") and prognosis
("Predictor C"), which will be launched in 2012 in its own ISO 15189 certified
service laboratory. Using its state-of-the-art technologies in tissue and blood
sample collection, molecular pathology, Xenopatient™ platform, genome-wide
profiling, data mining, and biostatistics, the company collaborates with
clinical, pharmaceutical, and diagnostic partners. Signature Diagnostics
sponsors and conducts large prospective, multicenter clinical trials with more
than 33 primary care hospitals and several dozen colonoscopy centers in Germany
to discover and validate biomarkers in oncology.
--- End of Message ---
Hermannswerder 20 A Potsdam Germany
Press release (PDF):
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Signature Diagnostics via Thomson Reuters ONE